However, another histone lysine modification enzyme, EZH2 (25.6% vs. 8.6%, p = 0.046), showed decreased immunoreactivity in BM compared with lung adenocarcinoma, indicating that the expression of MLL4 and UTX was decreased in BM (Table 2). This evidence concerns the gene EZH2 and lung adenocarcinoma.